Pulmonary hypertension in children may result from reduced activity of gene regulator

March 06, 2009

AUGUSTA, Ga. - Too little activity by gene regulators called PPARs appears to be a major player in the irreversible lung damage that can occur in children with heart defects, researchers say.

If they are right, drugs already under study to boost PPAR signaling in adults with lung injuries, may help these infants restore a healthy balance of blood vessel dilation and contraction, preventing the remodeling that transforms flexible blood vessels into rigid pipes and the pulmonary hypertension that often results.

"These drugs might be another therapy where you can treat some of the underlying mechanisms that have become deranged and reset the clock; essentially you can help the body go back to normal," said Dr. Stephen Black, a cell and molecular physiologist at the Medical College of Georgia's Vascular Biology Center.

About 1 percent of children are born with a heart defect with half requiring surgery. Improved surgical and medical treatments have improved survival rates for these children. Still their risk of related lung disease also can be deadly, researchers say as the high blood flow these defects produce pummels the lungs, turning flexible pulmonary blood vessels into rigid pipes, said Dr. Black, who co-directs the Cardiovascular Discovery Institute in the MCG School of Medicine.

Dr. Black and his colleague, Dr. Jeffrey Fineman, a whole-animal physiologist and physician at the University of California, San Francisco, want to understand the molecular mechanisms that disrupt regulatory mechanisms of the inner lining of blood vessels, or endothelium, and put children at increased risk. Dr. Black is principal investigator on two new National Institutes of Health grants and co-investigator on a third with Dr. Fineman to help dissect the dysregulation.

In a surgically created animal model of a congenital heart defect that causes too much pulmonary blood flow, they have already shown PPARs - peroxisome proliferator-activated receptors - are down regulated. In these lambs, whose four-chambered hearts are essentially identical to humans, agonists to boost PPAR activity prevent the usual endothelial dysfunction that occurs in the first few weeks after birth. Conversely, PPAR antagonists cause endothelial dysfunction without the underlying heart defect.

At its core, endothelial dysfunction is decreased ability of blood vessels to dilate and increased ability to thicken. That's just what MCG and UCSF researchers have seen in their animal model: increased expression of genes that cause blood vessels to constrict and reduced expression of those that enable dilation. They also are learning that the imbalance results from synergistic factors.

There's increased presence of reactive oxygen species which scavenge nitric oxide, a powerful dilator. There's also more asymmetric dimethyl arginine, or ADMA, which inhibits nitric oxide production, making bad matters worse. Nitric oxide synthase uses arginine to make nitric oxide and ADMA, an arginine analogue, can bind to the nitric oxide precursor so it instead becomes a source for free radical generation. Genes that regulate transfer of carnitine, an amino acid that regulates energy metabolism in the cell, also are out of whack so the cell's energy plants, or mitochondria, don't produce adequate energy but do start producing free radicals. Interestingly, the researchers have evidence that the carnitine genes are regulated by PPAR. And, they have documented an early increase in ADMA in their animal model and are studying its impact on cell signaling.

The way it's supposed to work is all about balance: the same amount of blood that comes into the heart being pumped to the lungs to pick up oxygen then going back to the heart to be pumped to the body. In their animal model, and in some children with heart defects, three times more blood goes back to the lungs than to the body. The shear force this exerts on the blood vessel lining sets in motion the resulting imbalance of contraction, dilation and more.

When a heart defect is the cause, pulmonary hypertension develops the first few weeks after birth, when previously idle lungs start getting hammered with excessive blood volume. In one of the worst case scenarios, pulmonary hypertension can preclude surgery to repair the heart defect that's causing the problem.

Other babies don't have heart defects but still are in deep and immediate trouble at birth. One reason is meconium aspiration, when stool in the amniotic fluid gets inside a baby's lungs before birth so lungs can't function properly afterward.

Dr. Black suspects that underlying mechanisms that cause endothelial dysfunction and pulmonary hypertension in both scenarios have PPAR in common.

If all continues to go well, the researchers hope to begin clinical trials of PPAR agonists in 2010.

Medical College of Georgia

---

---

	Pulmonary Hypertension by Norbert F. Voelkel MD (Author) Pulmonary hypertension is a world-wide problem which is gaining greater attention. Pulmonary hypertension is likely more frequently diagnosed now when compared to ten or twenty years ago because of the use and interpretation of echocardiograms. Pulmonary Hypertension will investigate and discuss concepts which will address the issue of etiology of pulmonary hypertension, its pathobiology with its close proximity to cancer, and the consequences of severe PH which is right heart failure and death.
	Pulmonary Hypertension: A Patient's Survival Guide by Gail Boyer Hayes (Author), Maureen Keane M.S. (Author), Ronald J. Oudiz (Editor) Brand New Paperback, shrink wrapped, in excellent condition. Ready to ship...(car)
	Pulmonary Hypertension (Contemporary Cardiology) by Nicholas S. Hill (Author), Harrison W. Farber (Author) This timely volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. The new therapies have led to significant improvements in patient function, quality of life and survival. In this book, expert authors describe these new therapies. It will be of interest not only to cardiologists, pulmonary specialists and rheumatologists, but also many nurses and pharmacotherapists.
	Pulmonary Arterial Hypertension: Diagnosis and Evidence - Based Treatment by Robyn Barst (Author) First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patientsFrom the PAH Association, the leading experts in fieldIncorporates the latest AACP management guidelinesIncludes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical TreatmentAimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH
	Pulmonary Arterial Hypertension (The Facts) by Clive Handler (Author), Gerry Coghlan (Author) Pulmonary arterial hypertension (PAH) is a high blood pressure in the arteries that supply the lungs with blood. Patients with mild PAH, particularly young patients, may feel quite well and get breathless or tired only with vigorous exertion. Those with severe PAH may get breathless on minimal exertion and feel tired, exhausted and experience chest pain, forceful heart beats, dizzy turns, loss of appetite, and have swelling of the legs due to fluid retention. This book will help patients and their families understand what PAH is, and advise them on how to cope with their illness. In the UK patients with PAH are referred to one of the eight National Pulmonary Hypertension centres staffed by a team of specialist doctors, nurses, pharmacists, and other staff who are experienced and...
	Pulmonary hypertension (PH) Miniatlas by Letbar Asociados S.A. Pulmonary hypertension is a disease with severe consequences on the quality of life of patients. It is a disorder that may affect individuals of all ages and races, though certain cases have evidenced a genetic predisposition to develop the disease. Initial symptoms are relatively nonspecific, which makes it difficult to establish early diagnosis.As the disease advances, these symptoms which with certain behavioral changes allow leading an acceptable life, become highly disabling. Usual activities that form part of everyday life such as the simple act of walking becomes difficult. The prognosis of pulmonary hypertension is poor, though recent data has indicated that the life expectancy is currently higher than that estimated years ago. Research done over the last few years has attempted...
	What You Always Wanted To Know About Pulmonary Hypertension (Medical Basic Guides) by Jazzybee Publishing "What You Always Wanted To Know About..." are fully researched, straight-to-the-point, easily understandable and most comprehensive medical ebooks and guides for everybody. Whether you are just interested in the topic of the book or you are directly affected by it, these books can really help you with the information you need. All books including interactive tables-of-contents, this is your step toward new insights and informations. The contents of this book: What Is Pulmonary Hypertension? Overview Outlook Types of Pulmonary Hypertension Other Names for Pulmonary Hypertension What Causes Pulmonary Hypertension? Who Is At Risk for Pulmonary Hypertension? What Are the Signs and Symptoms of Pulmonary Hypertension? How...
	Pulmonary Hypertension (Lung Biology in Health and Disease) by Marc Humbert (Editor), Joseph P. Lynch III (Editor) Written by internationally recognized experts, Pulmonary Hypertension bridges the gap between pulmonology and cardiology to provide clinicians in both disciplines with knowledge of the signs, symptoms, diagnosis, and pharmacologic and surgical treatments for pulmonary hypertension (PH). Through the use of clinical trials, this ground-breaking text supplies a comprehensive review of both the primary and secondary clinical and investigative aspects of this condition. Discussing controversies and concepts in PH diagnosis and management, this guide explores: classification and epidemiology, pathology, pathogenesis, genetics, and diagnosis of PH causes of the condition, such as idiopathic pulmonary arterial hypertension (IPAH) PAH-complicating connective tissue diseases (CTD),...
	Pulmonary Arterial Hypertension: Pocketbook by Stewart Simon (Author) This pocketbook is a concise summary of latest evidence-based information on the diagnosis, assessment and treatment of pulmonary arterial hypertension. Dr Simon Stewart is one of the world's leading nursing experts on cardiac disease, especially heart failure. Highly illustrated, clearly and succinctly written, the book provides an introduction to pulmonary arterial hypertension. It contains clear guidelines for the effective treatment of pulmonary arterial hypertension and emphasizes the need for screening of high-risk patients and outlines the range and effectiveness of treatment options once PAH has been diagnosed.
	A Clinician's Guide to Pulmonary Arterial Hypertension by Simon Stewart (Author) A Clinician's Guide to Pulmonary Arterial Hypertension, Second Edition enhances the overall 'PAH awareness' of the wider clinical community, and outlines the need for screening, effective diagnosis and beneficial treatment. Topics include: